CY1116336T1 - Αντισωματα εναντι ανασυνδυασμενης γλυκοπρωτεϊνης vi του υποδοχεα αιμοπεταλιων κολλαγονου - Google Patents
Αντισωματα εναντι ανασυνδυασμενης γλυκοπρωτεϊνης vi του υποδοχεα αιμοπεταλιων κολλαγονουInfo
- Publication number
- CY1116336T1 CY1116336T1 CY20151100344T CY151100344T CY1116336T1 CY 1116336 T1 CY1116336 T1 CY 1116336T1 CY 20151100344 T CY20151100344 T CY 20151100344T CY 151100344 T CY151100344 T CY 151100344T CY 1116336 T1 CY1116336 T1 CY 1116336T1
- Authority
- CY
- Cyprus
- Prior art keywords
- gpvi
- collagon
- receptor
- antibodies against
- glycoprotein
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title abstract 2
- 108090000288 Glycoproteins Proteins 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 208000015294 blood coagulation disease Diseases 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007119 pathological manifestation Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
- G01N2015/018—Platelets
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4728—Details alpha-Glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/222—Platelet disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
Abstract
Η εφεύρεση αναφέρεται στη Γλυκοπρωτεΐνη VI (GPVI), την απομόνωση, τον καθαρισμό της και τις μεθόδους για την ανασυνδυασμένη παραγωγή της. Ειδικά, η εφεύρεση σχετίζεται με τη χρήση της GPVI, κατά προτίμηση της ανασυνδυασμένης GPVI, στη θεραπεία διαταραχών, καθώς και παθολογικών εκδηλώσεων που συσχετίζονται άμεσα ή έμμεσα με διαταραχές της πήξης του αίματος, όπως θρομβωτικές και καρδιαγγειακές ασθένειες. Η εξωκυτταρικώς ανασυνδυασμένη πρωτεΐνη μπορεί επίσης να χρησιμοποιηθεί για τον καθορισμό αναλυτικών διαγνωστικών εξετάσεων, έτσι ώστε να βρεθούν πιθανοί αναστολείς της δεσμευμένης στη μεμβράνη GPVI, με σκοπό την αναστολή της ένωσης θρομβοκυττάρων και αιμοπεταλίων με το κολλαγόνο.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99109094 | 1999-05-07 | ||
| EP11001216.8A EP2341141B1 (en) | 1999-05-07 | 2000-04-25 | Antibodies against recombinant platelet collagen receptor glycoprotein VI |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116336T1 true CY1116336T1 (el) | 2017-02-08 |
Family
ID=8238132
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100731T CY1108190T1 (el) | 1999-05-07 | 2008-07-11 | Ανασυνδυασμενος υποδοχεας κολλαγονου αιμοπεταλιων της γλυκοπρωτεϊνης vi και η φαρμακευτικη του χρηση |
| CY20151100344T CY1116336T1 (el) | 1999-05-07 | 2015-04-09 | Αντισωματα εναντι ανασυνδυασμενης γλυκοπρωτεϊνης vi του υποδοχεα αιμοπεταλιων κολλαγονου |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100731T CY1108190T1 (el) | 1999-05-07 | 2008-07-11 | Ανασυνδυασμενος υποδοχεας κολλαγονου αιμοπεταλιων της γλυκοπρωτεϊνης vi και η φαρμακευτικη του χρηση |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US7928066B1 (el) |
| EP (3) | EP1942186B1 (el) |
| JP (2) | JP5480457B2 (el) |
| KR (1) | KR100703592B1 (el) |
| CN (1) | CN1253569C (el) |
| AR (1) | AR023848A1 (el) |
| AT (1) | ATE393223T1 (el) |
| AU (1) | AU775952B2 (el) |
| BR (1) | BRPI0010325B1 (el) |
| CA (1) | CA2372515C (el) |
| CY (2) | CY1108190T1 (el) |
| CZ (1) | CZ302693B6 (el) |
| DE (1) | DE60038675T2 (el) |
| DK (2) | DK1177289T3 (el) |
| ES (2) | ES2534652T3 (el) |
| HK (1) | HK1045714B (el) |
| HU (1) | HUP0201049A2 (el) |
| MX (1) | MXPA01011274A (el) |
| NO (1) | NO333408B1 (el) |
| PL (1) | PL204449B1 (el) |
| PT (2) | PT2341141E (el) |
| RU (1) | RU2287580C2 (el) |
| SI (1) | SI1177289T1 (el) |
| SK (1) | SK15762001A3 (el) |
| WO (1) | WO2000068377A1 (el) |
| ZA (1) | ZA200110071B (el) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK15762001A3 (sk) | 1999-05-07 | 2002-04-04 | Merck Patent Gmbh | Rekombinantný doštičkový kolagénový receptor glykoproteínu VI a jeho farmaceutické použitie |
| US7291714B1 (en) | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US6245527B1 (en) | 1999-06-30 | 2001-06-12 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof |
| US20040001826A1 (en) | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| AU7097400A (en) * | 1999-09-01 | 2001-03-26 | Otsuka Pharmaceutical Co., Ltd. | Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof |
| EP1224942A1 (en) * | 2001-01-23 | 2002-07-24 | Bernhard Dr. Nieswandt | Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases |
| EP1406929A2 (en) * | 2001-07-18 | 2004-04-14 | MERCK PATENT GmbH | Glycoprotein vi fusion proteins |
| US7531178B2 (en) | 2002-06-07 | 2009-05-12 | Trigen Gmbh | Immunoadhesin comprising a glycoprotein VI domain |
| EP1369128A1 (en) | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
| US20070071744A1 (en) | 2002-06-07 | 2007-03-29 | Gotz Munch | Agents which bind to epitopes of glycoprotein VI |
| DE102004017295A1 (de) * | 2004-04-05 | 2005-11-03 | Zlb Behring Gmbh | Verbindungen, welche die Entfernung von Rezeptoren von Zelllmembranen bewirken oder verhindern, und Verfahren zu ihrem Nachweis |
| CN1964990B (zh) | 2004-04-29 | 2012-12-12 | 大冢制药株式会社 | 糖蛋白ⅵ特异的抗体以及生产这些抗体的方法 |
| US7645592B2 (en) | 2004-04-29 | 2010-01-12 | Otsuka Pharmaceutical Co., Ltd. | Glycoprotein VI antibodies and methods of use thereof |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| RU2010121878A (ru) * | 2007-10-31 | 2011-12-10 | Оцука Фармасьютикал Ко., Лтд. (Jp) | Применения ингибитора гликопротеина vi (gpvi) |
| EP2694709B1 (en) | 2011-04-08 | 2016-09-14 | Prognosys Biosciences, Inc. | Peptide constructs and assay systems |
| EP3184544A1 (en) * | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Glycoprotein v inhibitors for use as coagulants |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT662088E (pt) | 1993-07-01 | 2002-06-28 | Merck Patent Gmbh | Inibidor da agregacao de plaquetas estimulada por colagenio |
| AU701576B2 (en) * | 1993-10-22 | 1999-02-04 | Trigen Limited | Platelet-derived growth factor analogues |
| AU5927398A (en) * | 1997-01-21 | 1998-08-07 | Human Genome Sciences, Inc. | Fc receptors and polypeptides |
| CA2250291A1 (en) * | 1997-01-29 | 1998-07-30 | Toray Industries Inc. | Chimeric proteins, their heterodimer complexes, and platelet substitutes |
| SK15762001A3 (sk) | 1999-05-07 | 2002-04-04 | Merck Patent Gmbh | Rekombinantný doštičkový kolagénový receptor glykoproteínu VI a jeho farmaceutické použitie |
| US7291714B1 (en) * | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US20040001826A1 (en) | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
| US6245527B1 (en) * | 1999-06-30 | 2001-06-12 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof |
| AU7097400A (en) * | 1999-09-01 | 2001-03-26 | Otsuka Pharmaceutical Co., Ltd. | Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof |
| EP1406929A2 (en) | 2001-07-18 | 2004-04-14 | MERCK PATENT GmbH | Glycoprotein vi fusion proteins |
| EP1538165A1 (en) | 2003-12-03 | 2005-06-08 | Procorde GmbH | Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4 |
-
2000
- 2000-04-25 SK SK1576-2001A patent/SK15762001A3/sk unknown
- 2000-04-25 DK DK00927035T patent/DK1177289T3/da active
- 2000-04-25 KR KR1020017014164A patent/KR100703592B1/ko not_active IP Right Cessation
- 2000-04-25 DK DK11001216T patent/DK2341141T3/en active
- 2000-04-25 US US09/959,802 patent/US7928066B1/en not_active Expired - Fee Related
- 2000-04-25 ES ES11001216.8T patent/ES2534652T3/es not_active Expired - Lifetime
- 2000-04-25 HU HU0201049A patent/HUP0201049A2/hu unknown
- 2000-04-25 EP EP08004264.1A patent/EP1942186B1/en not_active Expired - Lifetime
- 2000-04-25 CA CA2372515A patent/CA2372515C/en not_active Expired - Fee Related
- 2000-04-25 CZ CZ20013989A patent/CZ302693B6/cs not_active IP Right Cessation
- 2000-04-25 PL PL351437A patent/PL204449B1/pl unknown
- 2000-04-25 SI SI200030996T patent/SI1177289T1/sl unknown
- 2000-04-25 JP JP2000616343A patent/JP5480457B2/ja not_active Expired - Fee Related
- 2000-04-25 PT PT110012168T patent/PT2341141E/pt unknown
- 2000-04-25 EP EP11001216.8A patent/EP2341141B1/en not_active Expired - Lifetime
- 2000-04-25 PT PT00927035T patent/PT1177289E/pt unknown
- 2000-04-25 CN CNB008072922A patent/CN1253569C/zh not_active Expired - Fee Related
- 2000-04-25 MX MXPA01011274A patent/MXPA01011274A/es active IP Right Grant
- 2000-04-25 DE DE60038675T patent/DE60038675T2/de not_active Expired - Lifetime
- 2000-04-25 BR BRPI0010325A patent/BRPI0010325B1/pt not_active IP Right Cessation
- 2000-04-25 ES ES00927035T patent/ES2304347T3/es not_active Expired - Lifetime
- 2000-04-25 RU RU2001132140/13A patent/RU2287580C2/ru not_active IP Right Cessation
- 2000-04-25 AU AU45555/00A patent/AU775952B2/en not_active Ceased
- 2000-04-25 EP EP00927035A patent/EP1177289B1/en not_active Expired - Lifetime
- 2000-04-25 WO PCT/EP2000/003683 patent/WO2000068377A1/en active IP Right Grant
- 2000-04-25 AT AT00927035T patent/ATE393223T1/de active
- 2000-05-04 AR ARP000102136A patent/AR023848A1/es unknown
-
2001
- 2001-11-06 NO NO20015420A patent/NO333408B1/no not_active IP Right Cessation
- 2001-12-06 ZA ZA200110071A patent/ZA200110071B/xx unknown
-
2002
- 2002-09-26 HK HK02107061.7A patent/HK1045714B/zh not_active IP Right Cessation
-
2007
- 2007-03-21 US US11/689,392 patent/US20070172480A1/en not_active Abandoned
- 2007-03-21 US US11/689,385 patent/US8198030B2/en not_active Expired - Lifetime
-
2008
- 2008-07-11 CY CY20081100731T patent/CY1108190T1/el unknown
-
2010
- 2010-12-20 JP JP2010283409A patent/JP5554696B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-11 US US13/046,210 patent/US8278430B2/en not_active Expired - Lifetime
-
2015
- 2015-04-09 CY CY20151100344T patent/CY1116336T1/el unknown
-
2016
- 2016-03-08 US US15/064,157 patent/US20160207976A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116336T1 (el) | Αντισωματα εναντι ανασυνδυασμενης γλυκοπρωτεϊνης vi του υποδοχεα αιμοπεταλιων κολλαγονου | |
| Nanda et al. | Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling | |
| CY1118979T1 (el) | Αντισωματα που κατευθυνονται εναντι her-3 και χρησεις αυτων | |
| MEP53308A (en) | Novel peptides that bind to the erythropoietin receptor | |
| EA201290525A1 (ru) | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения | |
| DE60229059D1 (de) | Proteomimetische verbindungen und verfahren | |
| ECSP088262A (es) | Proteínas de fusión de albúmina | |
| DK0756638T3 (da) | Midler til behandling af forstyrrelser i blodkoagulationskaskaden | |
| MX2019005415A (es) | Anticuerpos de il-6 y uso de los mismos. | |
| CY1110679T1 (el) | Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
| DE602004012578D1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
| Galanakis et al. | Thromboelastographic phenotypes of fibrinogen and its variants: clinical and non-clinical implications | |
| EA200601217A1 (ru) | Новые конденсированные пирролокарбазолы | |
| AR030554A1 (es) | Moleculas similares a receptores il-17 y usos de las mismas | |
| ATE364050T1 (de) | Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak- rezeptors betreffen | |
| Wang et al. | Human platelets express functional thymic stromal lymphopoietin receptors: a potential role in platelet activation in acute coronary syndrome | |
| EA200700951A1 (ru) | БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG | |
| WO2006131512A3 (en) | Anti-thrombotic agents | |
| MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
| ATE372114T1 (de) | Verfahren zur erhöhung des testosteronspiegels | |
| ATE402958T1 (de) | Antagonisten des ige-rezeptors | |
| UA107177C2 (uk) | Імуногенна композиція цвс2 та спосіб приготування такої композиції | |
| DK1051491T3 (da) | Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf |